Conclusions
In summary, our work is the first report to reveal that miR-21 promotes
hypopharyngeal cancer induced transition of bone marrow mesenchymal stem
cells to cancer-associated fibroblasts, and also has an important effect
on cell cycle.
1. Piazza C, Paderno A, Ravanelli M, Pessina C. Clinical and
Radiological Evaluation of Hypopharyngeal Carcinoma. Adv
Otorhinolaryngol. 2019;83:35-46.
2. Zhou Y, Zhang Z, Chen H, Liu J, Lin R. Application of acellular
dermal matrix to reconstruct the defects after hypopharyngeal carcinoma
resection. Am J Otolaryngol. 2021;42(2):102847.
3. Budach W, Bolke E, Kammers K, Gerber PA, Orth K, Gripp S, et al.
Induction chemotherapy followed by concurrent radio-chemotherapy versus
concurrent radio-chemotherapy alone as treatment of locally advanced
squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of
randomized trials. Radiother Oncol. 2016;118(2):238-43.
4. Eckel HE, Bradley PJ. Treatment Options for Hypopharyngeal Cancer.
Adv Otorhinolaryngol. 2019;83:47-53.
5. Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA.
Mesenchymal stem cells for the treatment of neurodegenerative disease.
Regen Med. 2010;5(6):933-46.
6. Naldini L. Gene therapy returns to centre stage. Nature.
2015;526(7573):351-60.
7. Zhou W, Lin J, Zhao K, Jin K, He Q, Hu Y, et al. Single-Cell Profiles
and Clinically Useful Properties of Human Mesenchymal Stem Cells of
Adipose and Bone Marrow Origin. Am J Sports Med. 2019;47(7):1722-33.
8. Chu DT, Phuong TNT, Tien NLB, Tran DK, Thanh VV, Quang TL, et al. An
Update on the Progress of Isolation, Culture, Storage, and Clinical
Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells. Int J
Mol Sci. 2020;21(3).
9. Lin L, Huang K, Guo W, Zhou C, Wang G, Zhao Q. Conditioned medium of
the osteosarcoma cell line U2OS induces hBMSCs to exhibit
characteristics of carcinoma-associated fibroblasts via activation of
IL-6/STAT3 signalling. J Biochem. 2020;168(3):265-71.
10. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived
exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol.
2008;110(1):13-21.
11. Takahara K, Ii M, Inamoto T, Nakagawa T, Ibuki N, Yoshikawa Y, et
al. microRNA-145 Mediates the Inhibitory Effect of Adipose
Tissue-Derived Stromal Cells on Prostate Cancer. Stem Cells Dev.
2016;25(17):1290-8.
12. Wei J, Lu Y, Wang R, Xu X, Liu Q, He S, et al. MicroRNA-375:
potential cancer suppressor and therapeutic drug. Biosci Rep.
2021;41(9).
13. Zhang Z, Li X, Sun W, Yue S, Yang J, Li J, et al. Loss of exosomal
miR-320a from cancer-associated fibroblasts contributes to HCC
proliferation and metastasis. Cancer Lett. 2017;397:33-42.
14. Takikawa T, Masamune A, Yoshida N, Hamada S, Kogure T, Shimosegawa
T. Exosomes Derived From Pancreatic Stellate Cells: MicroRNA Signature
and Effects on Pancreatic Cancer Cells. Pancreas. 2017;46(1):19-27.
15. Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, Song SJ. Regulatory
Mechanism of MicroRNA Expression in Cancer. Int J Mol Sci. 2020;21(5).
16. Hussen BM, Hidayat HJ, Salihi A, Sabir DK, Taheri M, Ghafouri-Fard
S. MicroRNA: A signature for cancer progression. Biomed Pharmacother.
2021;138:111528.
17. Sekar D. miRNA 21: a novel biomarker in the treatment of bladder
cancer. Biomark Med. 2020;14(12):1065-7.
18. Chen W, Zhou SY, Mao L, Zhang HD, Sun DW, Zhang JY, et al. Crosstalk
between TGF-beta signaling and miRNAs in breast cancer metastasis. Tumor
Biol. 2016;37(8):10011-9.
19. Wei YY, Schober A. MicroRNA regulation of macrophages in human
pathologies. Cell Mol Life Sci. 2016;73(18):3473-95.
20. Wang L, Mou Y, Meng D, Sun Y, Chen X, Yang X, et al. MicroRNA-203
inhibits tumour growth and metastasis through PDPN. Clin Otolaryngol.
2017;42(3):620-8.
21. Fukumoto I, Kinoshita T, Hanazawa T, Kikkawa N, Chiyomaru T, Enokida
H, et al. Identification of tumour suppressive microRNA-451a in
hypopharyngeal squamous cell carcinoma based on microRNA expression
signature. Br J Cancer. 2014;111(2):386-94.
22. Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, et
al. miR-489 is a tumour-suppressive miRNA target PTPN11 in
hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer.
2010;103(6):877-84.
Fig. 1 Up-regulation of miR-21 in hypopharyngeal cancer and
FaDu cells. a. The expression level of miR-21 in HC (hypopharyngeal
cancer) and control (normal tissue). b. The expression level of miR-21
in FaDu cells and control (293T cell). All the data are presented as
mean ± SD (Student’s t-test). **p < 0.01.
Fig. 2 Isolation and identification of exosomes from
hypopharyngeal cancer. a. Particle size distribution curve of diluted
exosomes from FaDu cells. b. Exosomes shot by electron microscope.
Fig. 3 Exosomes from FaDu cells promoted CAFs-like features in
hBMSCs. a. Microscopic observation results showed the growth state of
CAF-like cells in FaDu-exo+BMSC group and control. Left :293T-exo+BMSC.
Right: Fadu-exo+BMSC. b. The expression level of α-SMA, FAP and GAPDH in
hBMSCs on different days were analyzed by western blot. The GAPDH was
used as a control. c-d. The α-SMA and FAP expression level in hBMSCs
were analyzed by qRT-PCR on different days. e-g. Flow cytometry results
showed the cell proportion of G1, S and G2 phase in FaDu-exo+BMSC group
and control. All experiments were performed in triplicate and presented
as mean ± SD. *p < 0.05, **p < 0.01. ***p
< 0.001. ****p < 0.0001.
Fig. 4 Exosomes with knock-out of miR-21 inhibited CAFs-like
features in hBMSCs. a. The expression level of miR-21 in exosomes or
FaDu cells with miR-21 inhibited or uninhibited were analyzed by
qRT-PCR. b-d. The α-SMA, FAP and GAPDH expression level of hBMSCs in
miR-21 inhibitor-treated group and control were analyzed by western blot
(b) and qRT-PCR (c-d) on different days. The GAPDH was used as a
control. e. Microscopic observation results showed the growth state of
CAF-like cells in miR-21 inhibitor treated group and control. Left:
Fadu-Exo+hBMSCs. Right: miR-21-inhibitor-Fadu-Exo+hBMSCs. f-h. Flow
cytometry results showed the cell proportion of G1, S, and G2 phase in
miR-21 inhibitor-treated group and control. All experiments were
performed in triplicate and presented as mean ± SD. *p < 0.05,
**p < 0.01. ***p < 0.001. ****p < 0.0001.
Table.1 Particle size distribution of exosomes from
hypopharyngeal cancer